A widely prescribed antibiotic that many families consider routine may, in rare cases, be linked to life-threatening breathing problems in otherwise healthy kids and young adults.
A surprising safety signal
A large study of adolescents and young adults found that trimethoprim-sulfamethoxazole (TMP-SMX) – an antibiotic often used for acne, urinary tract infections, and skin infections – was associated with a higher risk of acute respiratory failure compared with some other common antibiotics in the same age group. The overall likelihood of this severe complication remained very low, but the relative increase in risk compared with other drugs was notable and understandably alarming for parents and patients.
What the new study actually found
Researchers in Ontario analyzed health data for 10- to 25-year-olds who were considered generally healthy and were newly prescribed oral TMP-SMX, amoxicillin, or cephalosporin antibiotics for at least three days between April 2002 and August 2023. They chose amoxicillin and cephalosporins as comparison drugs because they treat similar infections and have overlapping patterns of bacterial coverage, making them reasonable alternatives in many clinical situations.
The main outcome they tracked was whether a patient ended up in the hospital within 30 days with acute respiratory failure, meaning the lungs suddenly could not provide enough oxygen or remove enough carbon dioxide, often requiring intensive care and breathing support. In the comparison between TMP-SMX and amoxicillin, 44,801 patients took TMP-SMX and 530,417 took amoxicillin, with a median treatment duration of seven days in both groups. Among those on TMP-SMX, 15 patients (0.03%) had a hospital visit for acute respiratory failure, compared with 49 patients (0.01%) in the amoxicillin group, corresponding to a weighted risk ratio of 2.79 and a weighted risk difference of 0.02 percentage points.
When TMP-SMX was compared with cephalosporins in a separate group of 248,236 adolescents and young adults (median age 19 years; about three-quarters female), 51,197 received TMP-SMX and 197,039 received cephalosporins. In this analysis, 17 patients taking TMP-SMX (0.03%) experienced acute respiratory failure, versus only 3 patients (0.01%) on cephalosporins, resulting in a weighted risk ratio of 2.85 and a risk difference of 0.02 percentage points. To put these numbers into more practical terms, the “number needed to harm” was 4,976 for TMP-SMX compared with amoxicillin and 4,046 for TMP-SMX compared with cephalosporins – meaning thousands of patients would, on average, need to be treated with TMP-SMX instead of these alternatives for one additional case of acute respiratory failure to occur.
Real-world cases behind the numbers
The new findings do not appear out of nowhere; they build on earlier case reports describing dramatic reactions in otherwise healthy teens and young adults after taking TMP-SMX, which is sold under brand names such as Bactrim and Septra. In a set of 19 such reports, several patients developed sudden, severe lung failure requiring intensive life support, including four who needed prolonged extracorporeal membrane oxygenation (ECMO), a form of heart–lung bypass that takes over the work of the lungs while they recover.
Tragically, two of those patients died, including a 17-year-old who endured more than a year in the hospital and spent 189 days on ECMO after a severe reaction to Bactrim. Stories like this understandably raise strong emotions and may make some families question whether a “routine” antibiotic is worth the risk at all. But here’s where it gets controversial: how should clinicians and patients balance these rare but devastating events against the very real danger of untreated infections and the benefits of an effective, inexpensive antibiotic that is widely relied upon worldwide?
Why regulators added a warning
These serious case reports prompted the U.S. Food and Drug Administration (FDA) to update safety information for TMP-SMX in 2021. The agency added a warning label to both oral and injectable formulations of Bactrim and Septra, advising healthcare professionals to be alert for new or worsening cough, shortness of breath, or rapid, shallow breathing when patients are using these medications.
The recent Ontario study is important because it is the first large, population-based analysis to support that earlier warning by showing an elevated relative risk of acute respiratory failure in a broad group of healthy adolescents and young adults. In other words, what started as a handful of concerning case reports now appears to be reflected, at a much smaller scale, in real-world population data. And this is the part most people miss: even when the absolute risk is tiny, a consistent safety signal in a large population can still influence prescribing decisions and monitoring practices.
How strong is the evidence?
The researchers reported that their main results held up across multiple sensitivity analyses, meaning they tried different reasonable ways of designing or adjusting the study and the increased relative risk associated with TMP-SMX remained. They also used an alternative study design to test the robustness of their findings, and the pattern still looked similar, which strengthens confidence that the association is not a statistical fluke.
However, the authors stressed that this was an observational study, which means it can show an association but cannot definitively prove that TMP-SMX directly causes acute respiratory failure. Other factors not fully captured in the administrative data could still play a role. For example, it is possible that in some cases the infections being treated – rather than the medication itself – contributed to the lung failure, especially if the underlying illness was more severe among those who received TMP-SMX.
Possible biological explanations
To explain why only a small fraction of patients seem to develop such extreme reactions, the authors suggest that some individuals might be genetically predisposed to severe side effects from TMP-SMX. This could involve differences in immune system genes or variations in enzymes responsible for metabolizing the drug, which might lead to an unusually intense immune or inflammatory response in the lungs in a susceptible minority.
At the same time, the researchers acknowledge that there may be alternative explanations. For instance, acute respiratory failure or acute respiratory distress syndrome could, in some cases, be driven more by the underlying infection than by the antibiotic, particularly if the infection itself is aggressive or not promptly controlled. This kind of uncertainty is common in drug safety research and is one reason why the authors call for further studies to replicate and refine these findings before drawing firm, causality-based conclusions.
What this means for patients and parents
For most people taking TMP-SMX, these results should not trigger panic but rather informed caution. The absolute risk of acute respiratory failure remains extremely low, and for many infections – particularly certain resistant urinary tract infections or specific types of skin infections – TMP-SMX can be a highly useful option. Doctors routinely weigh the benefits and risks of each antibiotic, considering factors like the suspected bacteria, local resistance patterns, allergies, and the patient’s overall health.
However, this research does reinforce the importance of monitoring for new or unusual breathing symptoms when starting any medication, especially in adolescents and young adults who are usually healthy and may dismiss early warning signs. If a patient on TMP-SMX suddenly develops shortness of breath, persistent cough, or rapid, shallow breathing, it is essential to seek medical attention promptly and let the clinician know about the recent antibiotic exposure. And here’s where it gets controversial again: should clinicians now default to alternatives such as amoxicillin or cephalosporins when they are equally appropriate, reserving TMP-SMX for situations where its specific advantages clearly outweigh these rare risks?
The bottom line and an open question for you
Right now, the study’s authors emphasize that their findings support the existing FDA warning and suggest a real but small increase in risk, yet they also underline that the vast majority of patients taking TMP-SMX do not experience acute respiratory failure. More research – especially studies that look at genetic and immune factors – is needed to confirm who is truly at risk and to clarify how much of the danger stems from the drug versus the underlying infections it is used to treat. Until then, clinicians are encouraged to stay vigilant but not to abandon a useful medication unnecessarily.
So what do you think: should doctors be much more conservative with TMP-SMX in healthy teens and young adults, even if it means using potentially less effective or more expensive alternatives, or do the very low absolute numbers justify continuing current prescribing habits as long as patients are warned about early signs of trouble? Would you feel comfortable taking or giving this antibiotic after hearing about these rare but severe cases, or would you push for a different option next time – and why?
